8-KExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Exhibit Filing (Feb 17, 2006)

Filed February 17, 2006For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K report on February 16, 2006, primarily to disclose new forms of stock-based compensation agreements. These documents detail the terms and conditions for various awards, including performance restricted stock, performance restricted stock units, and non-qualified stock options, all to be granted under the Abbott Laboratories 1996 Incentive Stock Program starting on or after February 17, 2006. This filing is significant for investors as it outlines the framework for future executive and employee compensation tied to company performance and stock value. Understanding these agreements is crucial for assessing potential dilution, executive incentives, and the company's overall approach to aligning employee interests with shareholder value. The specific terms of these awards, while not detailed in the 8-K itself, are governed by these newly disclosed forms.

Key Highlights

  • 1Disclosure of new forms for stock-based compensation awards under the 1996 Incentive Stock Program.
  • 2Includes agreements for Performance Restricted Stock, Performance Restricted Stock Units, and Non-Qualified Stock Options.
  • 3Awards are to be granted on or after February 17, 2006.
  • 4The filing indicates an update or expansion of the company's executive and employee incentive programs.
  • 5The forms provide the legal structure for how future equity compensation will be awarded and managed.
  • 6This is a routine disclosure related to equity compensation plans, not a report of a major operational or financial event.

Frequently Asked Questions

The primary purpose of this 8-K filing is to disclose the standard forms of various equity-based compensation agreements that Abbott Laboratories will use for awards granted under its 1996 Incentive Stock Program, effective on or after February 17, 2006. This includes performance restricted stock, performance restricted stock units, and non-qualified stock options.

No, this 8-K filing only provides the standard forms of the agreements. The specific terms for individual awards, such as the number of shares, performance metrics, vesting schedules, and exercise prices, are not detailed in these disclosed forms but would be specified in individual grant agreements.

This filing informs shareholders about the mechanisms through which future executive and employee compensation will be granted. It sets the framework for potential equity dilution and executive incentives, aligning management's interests with stock performance. Investors can refer to these disclosed forms to understand the terms governing future equity awards.

The 1996 Incentive Stock Program is the overarching plan under which these various stock-based awards are authorized. The filing indicates that Abbott Laboratories is continuing to utilize and potentially update its compensation strategies under this existing program by introducing new forms for granting awards.